plerixafor

Plerixafor (AMD-3329), a chemokine receptor antagonist, blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4.

Plerixafor octahydrochloride (JM3100 octahydrochloride) blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell (HSC) release from bone marrow and HSC movement into the peripheral circulation. Plerixafor is a bicyclam with hematopoietic stem cell-mobilizing activity.

Plerixafor-d4 is the deuterated form of Plerixafor. Plerixafor (AMD 3100) acts as a selective CXCR4 antagonist with an IC50 of 44 nM. It serves as an immunostimulant and a hematopoietic stem cell mobilizer, and it also functions as an allosteric agonist of CXCR7. Plerixafor inhibits the replication of HIV-1 and HIV-2 with an EC50 of 1-10 nM.

BIO5192 hydrate is a selective and potent integrin α4β1 (VLA-4) inhibitor (Kd < 10 pM). The compound selectively binds to α4β1 (IC50 = 1.8 nM) over various other integrins and results in a 30-fold increase in mobilization of murine hematopoietic stem and progenitors (HSPCs) over basal levels[1][2].